Monday, April 21, 2014 9:27:02 AM
Here is my article from September 2013.
article
My advice to investors is to sit this one out and wait for the Series D convertible shares to be absorbed into the float. I don't see an immediate monetization of either portfolio, which would justify the current $190M fully diluted value of the company. I do expect shares to be volatile on the upside and downside as traders try to take advantage of the low float. I would normally short an investment with the above fundamentals, but without options to hedge risk, tight float, lack of liquidity, and stock being extremely difficult to borrow I have chosen to eventually invest on the long side if/when the fully diluted value is at more attractive levels.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM